According to a new report by Polaris Market Research, the global opioid market was valued at USD 23.70 billion in 2024 and is projected to reach USD 28.45 billion by 2034, expanding at a CAGR of 1.8% over the 2025–2034 forecast period. Growth is underpinned by rising awareness of pain management options, increasing prevalence of traumatic injuries, and expanding healthcare infrastructure investment across key end-use regions.

What Is Driving Opioid Market Growth?

Demand is climbing as growing awareness and education around pain management converges with rising investment in healthcare infrastructure. Healthcare providers and patients are prioritizing comprehensive pain-management strategies, pushing opioid adoption across hospitals, trauma centers, and home-care settings. Polaris analysts note that nearly 50 million U.S. adults suffer from chronic pain, positioning the pain-management segment for sustained dominance through 2034, with North America emerging as the largest revenue contributor and Asia Pacific posting the fastest incremental gains.

Key Trends Shaping the Opioid Market Industry

Advanced Drug-Delivery Formulations

Innovations in extended-release and transdermal-patch delivery methods are improving patient compliance and pain-management effectiveness across hospital and home-care settings, reflecting steady product innovation in opioid formulations.

Growing Focus on Non-Addictive Alternatives and Safety

Rising development of non-addictive opioid alternatives is addressing long-standing safety concerns, encouraging more healthcare providers to incorporate opioids confidently into broader pain-management strategies under an evolving regulatory landscape.

Expanding Access in Underserved and Rural Markets

Government-backed healthcare infrastructure initiatives — such as India’s roughly USD 7.7 billion Ayushman Bharat Health Infrastructure Mission — are extending pain-management access to rural and underserved populations, shaping the market outlook for opioid demand in emerging economies.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/opioid-market

Market Segmentation: Breaking Down the Opioid Market Market

Polaris segments the opioid market by class, product, release type, and application, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Release Type

The extended-release/long-acting opioid segment is expected to register significant growth at a higher CAGR through 2034, driven by the rising prevalence of extended pain and traumatic injuries requiring long-acting formulations, as efforts to reduce overdose risk increase preference for long-acting over short-acting opioids.

By Application

Pain management is projected to lead the opioid market share during the forecast period, driven by the rising prevalence of chronic and acute injuries that require effective pharmacological relief, positioning the segment to remain dominant through 2034.

By Class and Product

Across drug class and product lines, established formulations such as fentanyl, oxycodone, morphine, and hydrocodone continue to anchor prescription volumes, while manufacturers expand semi-synthetic and fully synthetic portfolios to meet diverse clinical pain-management needs.

Regional Outlook: Where Is Opioid Market Growing Fastest?

North America led the market in 2024 on the back of advanced healthcare infrastructure, with 7,066 hospitals across the U.S. and Canada supporting high prescription rates for pain management, while Asia Pacific is expected to post the fastest CAGR through 2034, driven by high population density and growing healthcare demand in aging societies such as Japan and China. Within North America, the U.S. remains the largest single market with more than 916,752 hospital beds; within Asia Pacific, India is a primary growth engine, supported by USD 22.52 billion in cumulative pharmaceutical FDI inflow since 2000. Europe rounds out the top three, supported by expanding pain-management guidelines and healthcare-provider training programs.

Competitive Landscape: Leading Opioid Market Companies

Key players profiled in the report include Johnson & Johnson Corporation, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Mallinckrodt Pharmaceuticals, who are focusing on portfolio expansion, R&D investment, and strategic partnerships to strengthen market position across the pain-management and extended-release segments outlined above. Recent moves include Trevena’s June 2024 NMPA approval for OLINVYK in China through partner Jiangsu Nhwa Pharmaceutical, and Neuraxpharm’s January 2023 launch of Neuraxpharm Belgium, both aimed at deepening share across Asia Pacific and Europe.

Why It Matters for Buyers Evaluating Market Entry

For stakeholders researching the opioid market, this report benchmarks market share, segment-level pricing, and forecast data — by class, product, release type, application, and region — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing suppliers, investors sizing entry points, and strategy teams tracking extended-release formulations as a growth adjacency.

About Polaris Market Research

Polaris Market Research is a B2B syndicated market research and consulting firm offering 5,000+ published reports across 20+ industry verticals, delivering data-backed insights to help businesses make informed decisions.

More Trending Latest Reports By Polaris Market Research:

Digital Workplace Market

Plant-Based Meat Market

Ethylene Propylene Diene Monomer (EPDM) Market

Blastic Plasmacytoid Dendritic Cell Neoplasm Market

EMI Shielding Market

EMI Shielding Market

Aramid Fiber Market

Plastic Packaging Market

Benzene Market